This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB9606Q_M.jpg
Incyte announced earnings per share of $0.55 on revenue of $733.24M. Analysts polled by Investing.com anticipated EPS of $0.458 on revenue of $750.25M.
Incyte shares are up 39.27% from the beginning of the year, still down 13.83% from its 52 week high of $88.26 set on June 28, 2021. They are outperforming the S&P 500 which is down 12.82% from the start of the year.
Incyte shares lost 3.84% in pre-market trade following the report.
Incyte’s report follows an earnings beat by UnitedHealth on April 14, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
